Prodrug Strategies for HCV Nucleoside Lead Development

HCV 核苷先导药物开发的前药策略

基本信息

项目摘要

DESCRIPTION (provided by applicant): More than 200 million people worldwide are estimated to be chronically infected with HCV and as a result, at risk for developing life-threatening liver diseases. The only treatment currently available is a combination therapy of pegylated interferon and Ribavirin, a nucleoside analogue. Unfortunately this combination has exhibited limited efficacy in less than half of treated patients, as well as being plagued with treatment- limiting side effects and toxicity. In addition, increasing reports of drug resistance to investigational small molecules in clinical trials are emerging, underscoring the need for new and more effective treatments. A number of modified nucleosides have exhibited potent activity as inhibitors of HCV polymerase, however problems with ineffective delivery, toxicity, instability and/or poor pharmacokinetics have rendered many promising analogues unsuitable, thus many researchers are turning to use of a prodrug, or "masking" group, on the 5'-OH of the nucleoside, to overcome these problems. This application focuses on a series of expanded purine nucleoside analogues that we anticipate will exhibit potent activity against the HCV RNA-dependent RNA polymerase (RdRp) NS5B due to a number of strategically designed structural features. The impact of this application is two-fold; one, the medicinal discoveries could ultimately have a global impact, as more effective HCV treatments are desperately needed. In addition, the basic scientific impacts include expanding the breadth of our knowledge of drug delivery methods for specific targeting of the HCV NS5B polymerase, as well as liver cells. In addition, new and improved methodology for nucleoside analogue synthesis will be investigated. As such, the scientific impact of this work goes beyond just global health research, but will also provide valuable training for students, as the synthetic organic and drug delivery methodologies and the information obtained about polymerases will be highly applicable across a broad scope of diseases.
描述(由申请人提供):据估计,全世界有超过2亿人慢性感染HCV,因此有发生危及生命的肝病的风险。目前唯一可用的治疗方法是聚乙二醇干扰素和核苷类似物病毒唑的联合治疗。不幸的是,这种组合在不到一半的治疗患者中表现出有限的功效,并且受到治疗限制性副作用和毒性的困扰。此外,越来越多的报告显示,在临床试验中对研究性小分子的耐药性正在出现,这强调了对新的和更有效的治疗方法的需求。许多修饰的核苷已经显示出作为HCV聚合酶抑制剂的有效活性,然而,无效递送、毒性、不稳定性和/或不良药代动力学的问题使得许多有希望的类似物不适合,因此许多研究人员转向在核苷的5 '-OH上使用前药或“掩蔽”基团来克服这些问题。本申请的重点是一系列扩展的嘌呤核苷类似物,我们预计将表现出有效的活性对HCV RNA依赖的RNA聚合酶(RdRp)NS 5 B由于一些战略性设计的结构特征。这种应用的影响是双重的;第一,医学发现最终可能产生全球影响,因为迫切需要更有效的HCV治疗。此外,基本的科学影响包括扩大我们对HCV NS 5 B聚合酶以及肝细胞特异性靶向药物递送方法的知识广度。此外,新的和改进的核苷类似物的合成方法将进行调查。因此,这项工作的科学影响不仅仅是全球健康研究,而且还将为学生提供有价值的培训,因为合成有机和药物输送方法以及获得的有关聚合酶的信息将高度适用于广泛的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Katherine L Seley-Radtke其他文献

Katherine L Seley-Radtke的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Katherine L Seley-Radtke', 18)}}的其他基金

2023 2023 Nucleosides, Nucleotides and Oligonucleotides GRC & GRS
2023 2023 核苷、核苷酸和寡核苷酸 GRC
  • 批准号:
    10609239
  • 财政年份:
    2023
  • 资助金额:
    $ 20.58万
  • 项目类别:
A Flexible Approach to Inhibiting HIV NCp7
抑制 HIV NCp7 的灵活方法
  • 批准号:
    9008023
  • 财政年份:
    2015
  • 资助金额:
    $ 20.58万
  • 项目类别:
A Flexible Approach to Avoid Viral Escape Mutations
避免病毒逃逸突变的灵活方法
  • 批准号:
    8436187
  • 财政年份:
    2012
  • 资助金额:
    $ 20.58万
  • 项目类别:
Prodrug Strategies for HCV Nucleoside Lead Development
HCV 核苷先导药物开发的前药策略
  • 批准号:
    8249663
  • 财政年份:
    2012
  • 资助金额:
    $ 20.58万
  • 项目类别:
A Flexible Approach to Avoid Viral Escape Mutations
避免病毒逃逸突变的灵活方法
  • 批准号:
    8228586
  • 财政年份:
    2012
  • 资助金额:
    $ 20.58万
  • 项目类别:
Unnatural Base Pairs as DNA Bioprobes
作为 DNA 生物探针的非天然碱基对
  • 批准号:
    7931182
  • 财政年份:
    2009
  • 资助金额:
    $ 20.58万
  • 项目类别:
Unnatural Base Pairs as DNA Bioprobes
作为 DNA 生物探针的非天然碱基对
  • 批准号:
    6898670
  • 财政年份:
    2005
  • 资助金额:
    $ 20.58万
  • 项目类别:
Unnatural Base Pairs as DNA Bioprobes
作为 DNA 生物探针的非天然碱基对
  • 批准号:
    7232098
  • 财政年份:
    2005
  • 资助金额:
    $ 20.58万
  • 项目类别:
Unnatural Base Pairs as DNA Bioprobes
作为 DNA 生物探针的非天然碱基对
  • 批准号:
    7418933
  • 财政年份:
    2005
  • 资助金额:
    $ 20.58万
  • 项目类别:
Unnatural Base Pairs as DNA Bioprobes
作为 DNA 生物探针的非天然碱基对
  • 批准号:
    7070793
  • 财政年份:
    2005
  • 资助金额:
    $ 20.58万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 20.58万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 20.58万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 20.58万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 20.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 20.58万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 20.58万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 20.58万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 20.58万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 20.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 20.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了